Cargando…
Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Patients with non–Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM responses after booster vaccination against recent SARS-CoV-2...
Autores principales: | Chang, Andres, Akhtar, Akil, Lai, Lilin, Orellana-Noia, Victor M., Linderman, Susanne L., McCook-Veal, Ashley A., Switchenko, Jeffrey M., Saini, Manpreet, Valanparambil, Rajesh M., Blum, Kristie A., Allen, Pamela B., Lechowicz, Mary Jo, Romancik, Jason T., Ayers, Amy, Leal, Alyssa, O'Leary, Colin B., Churnetski, Michael C., Baird, Katelin, Kives, Melissa, Wrammert, Jens, Nooka, Ajay K., Koff, Jean L., Dhodapkar, Madhav V., Suthar, Mehul S., Cohen, Jonathon B., Ahmed, Rafi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833496/ https://www.ncbi.nlm.nih.gov/pubmed/36644323 http://dx.doi.org/10.1158/2767-9764.CRC-22-0471 |
Ejemplares similares
-
Poster: CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022) -
CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022) -
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
por: Valanparambil, Rajesh M., et al.
Publicado: (2023) -
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies
por: Chang, Andres, et al.
Publicado: (2023) -
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma
por: Nooka, Ajay K., et al.
Publicado: (2022)